Group 1 - The company Shapais (603168) announced that its 2025 semi-annual performance briefing is scheduled for September 16, 2025 [1]

证券代码：603168 证券简称：莎普爱思 公告编号：临2025-052 浙江莎普爱思药业股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、说明会类型 公司已于 2025 年 8 月 30 日在上海证券交易所网站（www.sse.com.cn）披露 了《浙江莎普爱思药业股份有限公司 2025 年半年度报告》及《浙江莎普爱思药 业股份有限公司 2025 年半年度报告摘要》。为便于广大投资者更加全面深入地 会议召开时间：2025 年 9 月 16 日（星期二）15:30-16:30 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 会 议 问 题 征 集 ： 投 资 者 可 于 2025 年 9 月 16 日 前 访 问 网 址 https://eseb.cn/1rcZywJXSKc 或使用微信扫描下方小程序码进行会前提问， 浙江莎普爱思药业股份有限公司（以下简称"公司"）将通过本次业绩 说明会，在信息披露允许范围内 ...

浙江莎普爱思药业股份有限公司 2025 年第一次临时股东大会会议资料 浙江莎普爱思药业股份有限公司 2025 年第一次临时股东大会 会 议 资 料 二〇二五年九月十六日 0 浙江莎普爱思药业股份有限公司 2025 年第一次临时股东大会会议资料 目 录 | 2025 年第一次临时股东大会会议须知 | 2 | | --- | --- | | 2025 年第一次临时股东大会会议议程 | 4 | | 2025 年第一次临时股东大会会议议案 | 5 | | 议案一：关于取消监事会、修订《公司章程》及办理工商变更登记的议案 | 5 | | 议案二：关于修订公司部分治理制度的议案 | 6 | 1 浙江莎普爱思药业股份有限公司 2025 年第一次临时股东大会会议资料 浙江莎普爱思药业股份有限公司 2025 年第一次临时股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证大 会的顺利进行，根据《公司章程》、公司《股东大会议事规则》等相关法律法规的 要求，特制定 2025 年第一次临时股东大会会议须知。 一、董事会以维护股东的合法权益、确保大会正常秩序和议事效率为原则，认 真履行《公司章程》中规定 ...

浙江莎普爱思药业股份有限公司（以下简称"公司"）于2025年8月29日召 开的第六届董事会第九次会议审议通过了《关于取消监事会、修订<公司章程> 及办理工商变更登记的议案》、逐项审议通过了《关于修订公司部分治理制度的 议案》，其中部分议案需提交公司2025年第一次临时股东大会审议，详细内容请 见公司于2025年8月30日在《中国证券报》、《上海证券报》、《证券时报》、 《证券日报》和上海证券交易所网站（www.sse.com.cn）上披露的公告。 为确保公司股东充分了解本次股东大会的相关信息，现将相关事项提示公告 如下： (一)股东大会类型和届次：2025 年第一次临时股东大会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相 结合的方式 证券代码：603168 证券简称：莎普爱思 公告编号：临 2025-051 浙江莎普爱思药业股份有限公司 关于召开 2025 年第一次临时股东大会的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 一、 召开会议的基本情况 (二)股东大会召集 ...

Core Viewpoint - On September 8, a total of 21 listed companies had their restricted shares unlocked, with a total market value of approximately 35.072 billion yuan [1] Summary by Category Restricted Share Unlocking - The specific situation of restricted share unlocking includes various companies and the types of shares being unlocked, such as equity incentive restricted circulation and pre-issue share restrictions [1] - Notable companies include: - Xizang Mining (000762) with 17,300 shares unlocked - Fida Environmental Protection (600526) with 9.284 million shares unlocked - Jichuan Pharmaceutical (600566) with 2.073 million shares unlocked - Nanguang Energy Storage (600995) with 2.234 billion shares unlocked, the largest among the listed companies [1] Market Impact - The total market value of the unlocked shares is significant, indicating potential liquidity changes in the market [1] - Companies like Xibu Gold (601069) and Shengtong Energy (001331) also had substantial amounts of shares unlocked, with 198 million and 126 million shares respectively [1]

Core Viewpoint - The major shareholder of Zhejiang Shapuaisi Pharmaceutical Co., Ltd., Chen Dekang, plans to reduce his stake in the company due to personal financial needs, which raises concerns about the company's future performance and governance [2][3]. Shareholder Changes - Chen Dekang, who currently holds 11.67% of the shares, intends to reduce his holdings by up to 2% of the total share capital within three months starting from September 25, 2025 [2]. - Chen Dekang has a long history with the company, having been its founder and former controlling shareholder, but he lost control in late 2018 when he transferred shares to the Lin brothers [3][4]. - Since losing control, Chen has been on a continuous selling spree, reducing his stake from 16.3% in 2021 to the current 11.67% [4][6]. Company Performance - Shapuaisi has faced financial difficulties, with losses reported in 2020 and 2024, totaling 1.79 billion and 1.23 billion respectively, leading to cumulative losses of 1.96 billion over five years [4][7]. - The company managed to achieve a profit of 0.22 billion in the first half of the current year, but this is minimal compared to its historical performance [4][7]. Market Position and Stock Performance - The company's stock price has significantly declined from over 50 yuan per share at its peak to below 10 yuan currently, indicating a lack of upward momentum [7][8]. - Despite attempts to integrate hospitals controlled by the Lin brothers into Shapuaisi, these acquisitions have not resulted in improved financial performance, with core product sales dropping by 80% from 2017 to 2024 [7].

Group 1 - The core point of the announcement is that Zhejiang Shapuaisi Pharmaceutical Co., Ltd.'s wholly-owned subsidiary has received approval for clinical trials of a new eye drop medication, which is intended for the treatment of presbyopia in adults [1][2]. - The drug, named Pilocarpine Hydrochloride Eye Drops, is classified as a Class 3 chemical drug and is currently in the clinical trial phase [1][3]. - The total research and development investment for the Pilocarpine Hydrochloride Eye Drops project has reached approximately 6.4457 million RMB [3]. Group 2 - The major shareholder, Mr. Chen Dekang, holds 43,871,004 shares, accounting for 11.67% of the total share capital of the company [7]. - Mr. Chen plans to reduce his holdings by up to 3,759,250 shares through centralized bidding and another 3,759,250 shares through block trading, totaling a maximum of 7,518,500 shares, which is 2.00% of the total share capital [7][8]. - The reduction plan is due to personal financial needs and will take place from September 25, 2025, to December 24, 2025 [7].

Summary of Key Points Core Viewpoint - The major shareholder of Zhejiang Shapuaisi Pharmaceutical Co., Ltd., Mr. Chen Dekang, plans to reduce his shareholding due to personal financial needs, with specific limits on the number of shares to be sold and the methods of sale [1][2]. Group 1: Shareholder Information - Mr. Chen Dekang holds 43,871,004 shares, representing 11.67% of the total shares [2]. - The shares held by Mr. Chen include 33,494,281 shares acquired before the IPO and 10,376,723 shares obtained through other means [2]. Group 2: Reduction Plan Details - The reduction plan allows for a maximum of 7,518,500 shares to be sold, which is up to 2.00% of the total share capital [2]. - The plan specifies that up to 3,759,250 shares may be sold through centralized bidding and another 3,759,250 shares through block trading [1][2]. - The reduction period is set from September 25, 2025, to December 24, 2025 [1][2]. Group 3: Compliance and Commitments - Mr. Chen has made prior commitments regarding shareholding, including a lock-up period and conditions under which he may reduce his holdings [3][4]. - The company and Mr. Chen will adhere to relevant laws and regulations during the reduction process, ensuring timely disclosure of information [6].

Group 1 - The company Zhejiang Shapuaisi Pharmaceutical Co., Ltd. announced that its wholly-owned subsidiary, Zhejiang Shapu Health Management Co., Ltd., has received the clinical trial approval notice for Pilocarpine Hydrochloride Eye Drops from the National Medical Products Administration [1] - The drug is classified as a Class 3 chemical drug and is intended for the treatment of presbyopia in adults [1] - The total research and development investment for the Pilocarpine Hydrochloride Eye Drops project has reached approximately 6.4457 million RMB [1]

Key Points - Tianpu Co., Ltd. announced a suspension of trading for stock verification due to multiple instances of abnormal trading fluctuations from August 22 to September 3, with a reminder for investors about market risks [1] - China Shipbuilding Industry Corporation announced a share exchange ratio of 1:0.1339 for the merger with China Shipbuilding, with the stock ceasing to be listed from September 5, 2025 [2] - Chengdu Huamei reported that its 40G high-precision RF ADC chip is still in the trial production stage and has not achieved mass sales, indicating market demand uncertainty [2] - Taihe Technology's sulfide solid electrolyte project is currently in the trial production phase and has not generated sales revenue [3] - Robotech signed a contract worth approximately €946.50 million for fully automated silicon photonic packaging equipment, expected to positively impact the company's future performance [4] - Wento Holdings reported that its cinema and gaming businesses are still in the recovery phase post-restructuring, with potential uncertainties in future operations [5] - Xibu Muye's fresh milk production increased by 4.8% month-on-month in August [6] - China Shipbuilding announced the implementation of a share exchange merger with China Heavy Industry [6] - Gansu Energy plans to invest CNY 40.89 billion in a wind-solar integrated project [6] - Xinhua Medical's endoscope cleaning workstation received a Class II medical device registration certificate [6]